JP2023553538A5 - - Google Patents
Info
- Publication number
- JP2023553538A5 JP2023553538A5 JP2023560246A JP2023560246A JP2023553538A5 JP 2023553538 A5 JP2023553538 A5 JP 2023553538A5 JP 2023560246 A JP2023560246 A JP 2023560246A JP 2023560246 A JP2023560246 A JP 2023560246A JP 2023553538 A5 JP2023553538 A5 JP 2023553538A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- aqueous pharmaceutical
- composition according
- arginine
- contain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063125277P | 2020-12-14 | 2020-12-14 | |
| US63/125,277 | 2020-12-14 | ||
| US202163186684P | 2021-05-10 | 2021-05-10 | |
| US63/186,684 | 2021-05-10 | ||
| PCT/US2021/063086 WO2022132636A1 (en) | 2020-12-14 | 2021-12-13 | High concentration formulations of anti-csf1 and anti-csf1r antibodies |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023553538A JP2023553538A (ja) | 2023-12-21 |
| JP2023553538A5 true JP2023553538A5 (https=) | 2024-12-12 |
Family
ID=81942250
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023560246A Pending JP2023553538A (ja) | 2020-12-14 | 2021-12-13 | 抗ｃｓｆ１および抗ｃｓｆ１ｒ抗体の高濃度製剤 |
Country Status (4)
| Country | Link |
|---|---|
| US (3) | US11419822B2 (https=) |
| EP (1) | EP4065161A4 (https=) |
| JP (1) | JP2023553538A (https=) |
| WO (1) | WO2022132636A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2022132636A1 (en) | 2020-12-14 | 2022-06-23 | AmMax Bio, Inc. | High concentration formulations of anti-csf1 and anti-csf1r antibodies |
| JP2024518536A (ja) * | 2021-05-12 | 2024-05-01 | アナプティスバイオ インコーポレイティッド | 抗体組成物 |
| WO2023019262A1 (en) * | 2021-08-12 | 2023-02-16 | AmMax Bio, Inc. | Targeted delivery of anti-csf1r antibodies |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JO3000B1 (ar) * | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
| PL2188313T3 (pl) * | 2007-08-21 | 2018-04-30 | Amgen, Inc. | Białka wiążące ludzki antygen c-fms |
| EP2458990B1 (en) | 2009-07-28 | 2016-03-30 | Merck Sharp & Dohme Corp. | Methods for producing high concentration lyophilized pharmaceutical formulations |
| BR112012013148A2 (pt) * | 2009-12-29 | 2017-03-21 | F Hoffmann - La Roche Ag | formulação farmacêutica e uso |
| SG11201610672YA (en) * | 2014-06-23 | 2017-01-27 | Five Prime Therapeutics Inc | Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r) |
| MX2017008218A (es) * | 2014-12-22 | 2017-10-18 | Five Prime Therapeutics Inc | Anticuerpos anti-csf1r para tratar pvns. |
| AU2020283742A1 (en) * | 2019-05-24 | 2021-09-16 | Elixiron Immunotherapeutics (hong Kong) Limited | Anti-CSF1R antibodies, IL10 fusion proteins, and uses thereof |
| WO2022132636A1 (en) | 2020-12-14 | 2022-06-23 | AmMax Bio, Inc. | High concentration formulations of anti-csf1 and anti-csf1r antibodies |
-
2021
- 2021-12-13 WO PCT/US2021/063086 patent/WO2022132636A1/en not_active Ceased
- 2021-12-13 JP JP2023560246A patent/JP2023553538A/ja active Pending
- 2021-12-13 US US17/549,785 patent/US11419822B2/en active Active
- 2021-12-13 EP EP21907560.3A patent/EP4065161A4/en active Pending
-
2022
- 2022-05-18 US US17/747,844 patent/US12178915B2/en active Active
-
2024
- 2024-11-19 US US18/952,613 patent/US20250073170A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7080263B2 (ja) | 高濃度の抗ｖｅｇｆ抗体を含有する安定状態のタンパク質溶液製剤 | |
| JP2023553538A5 (https=) | ||
| JP7715635B2 (ja) | イズロン酸２－スルファターゼを含むタンパク質分子の製剤 | |
| ES2900624T3 (es) | Formulación de anticuerpos | |
| US7879805B2 (en) | High temperature stable peptide formulation | |
| EP3681483B1 (en) | Process for lyophilized pharmaceutical formulation of a therapeutic protein | |
| JP2019512012A5 (https=) | ||
| JP2022105056A (ja) | 高濃度の抗ｖｅｇｆ抗体を含有するタンパク質溶液製剤 | |
| EP3675815A1 (en) | Daptomycin formulations | |
| JP2013525406A (ja) | 安定ｍｉａ／ｃｄ−ｒａｐ製剤 | |
| JP2025087851A (ja) | 安定な低粘度抗体製剤およびその使用 | |
| WO2022268214A1 (zh) | Pcsk9抑制剂和glp-1受体激动剂的药物组合 | |
| KR20220034053A (ko) | 재조합 단백질의 안정적인 제형 | |
| WO2017085151A1 (fr) | Composition a action rapide d'insuline comprenant un citrate substitue | |
| US11744902B2 (en) | Targeting technology to selectively express mRNAs in cardiomyocytes while avoiding stimulation of cardiac fibroblasts | |
| EP3207936B1 (en) | Stable peptide composition | |
| JPH1180021A (ja) | バンコマイシン注射剤 | |
| WO2018184541A1 (zh) | 英夫利西单抗冻干制剂 | |
| TR2023017070T (tr) | Pharmaceutical compositions of bevacizumab | |
| HK40033832A (en) | Process for lyophilized pharmaceutical formulation of a therapeutic protein | |
| HK40033832B (en) | Process for lyophilized pharmaceutical formulation of a therapeutic protein | |
| EA043419B1 (ru) | Способ получения лиофилизированного фармацевтического состава на основе терапевтического белка | |
| HK40064377A (en) | Formulations of protein molecules comprising iduronate 2-sulfatase |